ATG16L2

Across TCGA pan-cancer cohorts, ATG16L2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ATG16L2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATG16L2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATG16L2 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, KICH, and LIHC are the cancer types where ATG16L2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG16L2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.107	<.001	11	view →
KICH	All	All	−0.575	<.001	5	view →
LIHC	Female	All	+0.719	<.001	4	view →
LUSC	All	All	−0.635	<.001	4	view →
LUAD	All	All	−0.472	<.001	4	view →
CHOL	All	All	+1.303	<.001	3	view →
COAD	All	All	+0.391	.008	3	view →
KIRP	All	All	+0.455	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ATG16L2–KIRC

Open the KIRC breakdown →